Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06903065 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis
A Phase 1 study of MASH, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 20
- Study locations
NCT06903065: Active Phase 1 study of MASH, sponsored by Hoffmann-La Roche.
NCT06903065 is a Phase 1 study of MASH that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 50 participants, below the 156-participant average among 5 other MASH trials with a reported enrollment target (68% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06903065, a Phase 1 study of MASH, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity and activity of RO7790121 in participants with advanced metabolic dysfunction-associated steatohepatitis (MASH) fibrosis.
Conditions Studied
Interventions
- DRUG RO7790121
Study Locations (20)
Texas
- Pinnacle Clinical Research - Austin - Austin
- Bellaire Clinical Research, LLC - Bellaire
- DHR Health Institute for Research and Development - Edinburg
- Pinnacle Clinical Research Georgetown - Georgetown
- Pinnacle Clinical Research, PLLC - San Antonio
- GI Alliance - Southlake
Tennessee
- Innovative Clinical Research - Clarksville
- Gastroenterology Center of the MidSouth PC - Cordova
Jalisco
- Centro de Investigacion Clinica y Medicina Traslacional CIMeT - Guadalajara
- Hospital General de Occidente SSJ - Zapopan
Mexico CITY (federal District)
- Inovacion y Desarrollo en ciencias de la salud - Ciudad de Mxico
- Centro de Investigacion y Gastroenterologia - Mexico City
Arizona
- Adobe Clinical Research, LLC - Tucson
Florida
- Gastro Health Research - Miami - Miami
Georgia
- Gastrointestinal Specialists of Georgia, PC - Marietta
Louisiana
- Delta Research Partners, LLC (Bastrop) - Bastrop
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-04-14 |
| Est. Completion | 2026-12-30 |
| Phase | Phase 1 |
What the registry record for NCT06903065 still lists
NCT06903065 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 156-participant average among 5 other MASH trials with a reported enrollment target (68% lower).
The record links to 1 condition, with MASH appearing as the primary indexed condition, and to 1 intervention - of which RO7790121 is the first listed.
NCT06903065 names 20 study sites across 12 states, led by Texas, Tennessee, Jalisco.
Frequently Asked Questions
What is clinical trial NCT06903065 about?
NCT06903065 is a clinical study titled "A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis". The purpose of this study is to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity and activity of RO7790121 in participants with advanced metabolic dysfunction-associated steatohepatitis (MASH) fibrosis.
What is the current status of trial NCT06903065?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2025-04-14. Estimated completion is 2026-12-30.
What conditions does trial NCT06903065 study?
This clinical trial studies the following conditions: MASH.
What interventions are being tested in trial NCT06903065?
The interventions under investigation include: RO7790121 (DRUG).
Who is sponsoring clinical trial NCT06903065?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06903065 being conducted?
This trial has 20 study locations across Arizona, Florida, Georgia, Louisiana, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for MASH
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Endoscopic Ultrasound Shear Wave Elastography Study
RECRUITING
-
Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)
RECRUITING
-
Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
RECRUITING · NA
-
Digoxin In NASH (CODIN)
RECRUITING · Phase 2
-
ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI